Cronos Group (CRON) Set to Post Quarterly Earnings on Thursday

Cronos Group (NASDAQ:CRON) is projected to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of $0.03 per share and revenue of $51.15 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Cronos Group (NASDAQ:CRON) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.01 by $0.08. Cronos Group had a net margin of 39.08% and a return on equity of 4.85%. The business had revenue of $53.01 million during the quarter, compared to analyst estimates of $44.20 million. On average, analysts expect Cronos Group to post $0.12 EPS for the current fiscal year and $0.25 EPS for the next fiscal year.

Cronos Group Stock Up 1.5%

Shares of NASDAQ:CRON opened at $3.38 on Wednesday. Cronos Group has a 52 week low of $2.28 and a 52 week high of $3.61. The stock has a market capitalization of $1.25 billion, a P/E ratio of 30.27 and a beta of 0.96. The firm has a fifty day simple moving average of $3.30 and a two-hundred day simple moving average of $2.86.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on CRON. Wall Street Zen downgraded shares of Cronos Group from a “buy” rating to a “hold” rating in a report on Saturday, August 15th. Zacks Research upgraded Cronos Group from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 22nd. TD Securities reissued a “buy” rating on shares of Cronos Group in a research note on Monday, September 28th. Finally, Weiss Ratings upgraded Cronos Group from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 8th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Cronos Group presently has a consensus rating of “Buy” and a consensus price target of $2.30.

Cronos Group Company Profile

Cronos Group Inc is a Canadian cannabinoid company focused on developing, producing and commercializing cannabis and cannabis-derived consumer products. The company serves adult-use and medical cannabis markets through a portfolio of brands and sells products such as dried flower, pre-rolls, vaporizers, edibles, oils and other cannabis formats, subject to applicable regulations.

Its brand portfolio has included Spinach, which is positioned primarily in the adult-use cannabis market, as well as Lord Jones and PEACE NATURALS.